Order Now, Ships Today
One-time
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
SLU-PP-332 is a small-molecule pan estrogen-related receptor (ERR) agonist that preferentially activates ERRα while also engaging ERRβ and ERRγ. Each capsule contains 300 mcg of SLU-PP-332, provided in a 100-capsule bottle for studies on mitochondrial function, exercise mimetics and metabolic regulation.
This compound is manufactured for research use and qualified at ≥98% purity by HPLC. The accompanying Certificate of Analysis documents identity (C₁₈H₁₄N₂O₂), mass spectrometry data, purity profile, residual solvent levels and capsule fill verification at 300 mcg per unit.
Products from Elite Miami Peptides do not include usage instructions, as they are strictly for in vitro research and prohibited by law for human or animal use. Misuse or unlawful application will result in permanent denial of service.
Each vial contains exactly what’s indicated on the label. For instance, a 10mg vial contains precisely 10mg of lyophilized peptide. Researchers may divide it into smaller research portions—such as four 2.5mg aliquots—but the total content remains the same.
Yes. All peptides are supplied in lyophilized powder form and do not come reconstituted. Any extra materials required for research, such as solvents or diluents, must be obtained separately.
When stored as a dry powder, peptides remain stable for up to 2 years.
Once reconstituted, the solution should be kept refrigerated and is typically stable for up to 2 months under proper storage conditions.
SLU-PP-332 is a synthetic ERR pan-agonist that promotes transcriptional programs linked to mitochondrial biogenesis, oxidative metabolism and fatty-acid oxidation. In preclinical models, pharmacologic ERR activation with SLU-PP-332 has been used to study exercise-like signalling, metabolic syndrome and cardiac energetics.
SLU-PP-332 is often described as an “exercise-mimetic” research compound. Instead of making animals or cells perform physical activity, it turns on some of the same energy and mitochondrial pathways inside the lab, helping scientists investigate how improved cellular metabolism might influence heart, muscle and metabolic health markers. This material is for research use only and not for human consumption.
⚠️ Disclaimer: this product is not approved for medical use and is not intended to diagnose, treat, or prevent any disease. All information provided is for educational and research purposes only, and this product must never be used in humans or animals.
SLU-PP-332 was developed through structure-based design efforts aimed at creating potent ERR agonists with good activity across ERRα/β/γ. Since its first description, it has been adopted as a tool compound in metabolic, cardiovascular and aging studies to probe ERR-dependent control of mitochondrial function and exercise-responsive genes.
SLU-PP-332 (4-hydroxy-N'-(naphthalen-2-ylmethylidene)benzohydrazide) features a hydrazone linkage connecting a 4-hydroxybenzamide moiety to a naphthalene ring. Its molecular formula is C₁₈H₁₄N₂O₂ with a molecular weight of about 290.3 g/mol, and it exists predominantly in the Z-configuration at the C=N double bond, which is important for ERR binding.
In cell-based assays, SLU-PP-332 enhances ERR-driven transcription, upregulates targets such as pyruvate dehydrogenase kinase 4 and increases mitochondrial respiration in skeletal muscle myotubes. In mouse models, ERR agonism with SLU-PP-332 has been reported to improve markers of metabolic syndrome, increase exercise capacity, and support cardiac contractile function while reducing fibrosis and mitochondrial dysfunction.
Overall, SLU-PP-332 is used to switch on the same nuclear receptors that respond to endurance exercise, allowing researchers to test how “turning up” mitochondrial activity changes metabolism, muscle performance and heart health in non-clinical models. These findings are experimental and do not establish safety or efficacy for any disease in humans.
Billon C. et al. (2023). Synthetic ERR agonist induces exercise-like responses and enhances exercise capacity in mice. ACS Chemical Biology. ResearchGate +1 Xu W. et al. (2022). ERR pan-agonists, including SLU-PP-332, ameliorate heart failure via improved mitochondrial function. bioRxiv / Circulation Research. AHÁ Journals +2 BioRxiv +2 Giacomello E. et al. (2025). Exercise mimetics and ERR agonists in aging muscle. Mechanisms of Ageing and Development. PMC Wang M. et al. (2025). ERR agonists (SLU-PP-332, SLU-PP-915) and mitochondrial fatty-acid oxidation in cardiometabolic disease. Frontiers in Pharmacology. Frontiers
Delta Sleep-Inducing (DSIP)
Our specialists respond within minutes to any order or product inquiry.
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
By clicking the button above, you agree to receive marketing text messages from Elite Miami Peptides at the number provided. Consent is not a condition of purchase. Msg & data rates may apply. Reply STOP to cancel, HELP for help. View our Privacy Policy.
All compounds from Elite Miami Peptides are intended strictly for laboratory research purposes.
They are not for human use, consumption, or therapeutic applications.
Products are supplied exclusively to qualified professionals working in compliance with all applicable laws and regulations.
